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Although human pathologies have mostly been modeled using higher mammal systems such as mice, the lower vertebrate
zebrafish has gained tremendous attention as a model system. The advantages of zebrafish over classical vertebrate models are
multifactorial and include high genetic and organ system homology to humans, high fecundity, external fertilization, ease of
genetic manipulation, and transparency through early adulthood that enables powerful imaging modalities. This paper focuses on
four areas of human pathology that were developed and/or advanced significantly in zebrafish in the last decade. These areas are (1)
wound healing/restitution, (2) gastrointestinal diseases, (3) microbe-host interactions, and (4) genetic diseases and drug screens.
Important biological processes and pathologies explored include wound-healing responses, pancreatic cancer, inflammatory bowel
diseases, nonalcoholic fatty liver disease, and mycobacterium infection. The utility of zebrafish in screening for novel genes
important in various pathologies such as polycystic kidney disease is also discussed.
1. Introduction
Investigators have long utilized reductionist systems and
animal models to mimic and study basic processes regulating
cellular biology, organ function, and host homeostasis. While
much work has been accomplished and continues to be
undertaken in higher mammalian systems such as mice,
rats, and rabbits, important discoveries have also been made
using invertebrate systems such as Caenorhabditis elegans
and Drosophila melanogaster. For example, RNA interference
technology was first discovered in C. elegans [1], as was
the initial caspase enzyme, caspase-1 (ced-3 in C. elegans)
[2]. Similarly, it was in Drosophila melanogaster that
the innate signaling Toll-like receptors (TLRs) were first
identified via the discovery of the Toll gene, as was its
linkage to the nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-κB) signaling cascade [3]. In the
last ∼15 years, there has been a growing appreciation for
the vertebrate organism Danio rerio (zebrafish) as a tool
to study human disease [4]. As opposed to C. elegans and
Drosophila melanogaster, zebrafish is a vertebrate organ-
ism with physiological and anatomical characteristics of
its higher organism counterparts (see Figure 1 for a dia-
gram of larval zebrafish anatomy), while maintaining the
ease of use of a lower organism. The characteristics of
zebrafish that make them desirable tools for the study of
embryogenesis/development also make them useful for the
study of human pathologies. Zebrafish have a fully mapped
genome (http://www.sanger.ac.uk/Projects/D rerio/), which
has significant homology with the human genome, including
noncoding regions (∼60 per gene globally across all genes)
[5] suggesting that numerous genes involved in human
diseases could be matched in the zebrafish genome. Reverse
(morpholino knock-down, Targeting Induced Local Lesions
in Genome—TILLING [6]) and forward genetic (muta-
genesis, transgenic) approaches are well established and
commonly used to manipulate and characterize zebrafish
gene function.
Zebrafish are highly fecund and breed rapidly; a pair of
zebrafish produces over 100 embryos per clutch that are
usable for larval experiments as early as 3 days post fertiliza-
tion (dpf). These larvae are transparent through 7 dpf, and
this can be extended to up to 9–14 dpf with the addition
of the melanocyte inhibitor phenylthiourea. Moreover, the













Figure 1: Diagram of zebrafish anatomy. A representative image
of a transparent, 6 dpf larvae captured with brightfield microscopy.
Organs and anatomical features are denoted in the figure. SB: swim
bladder. Scale bar is 1 mm.
recent generation of transparent adult zebrafish such as
the Casper line adds new imaging possibilities [7]. The
transparency of zebrafish, in conjunction with sophisticated
utilization of fluorescent technology to mark signaling
proteins or cellular entities, allows for powerful time-lapse
imaging of biological and disease processes. Additionally, the
vertebrate zebrafish has many features commonly found in
mammals, including an innate immune system composed
of neutrophils, NK cells, and monocyte/macrophages with
functionality by 48 hours post fertilization (hpf) [8, 9] and
an adaptive immune system that is fully functional at 4–6
weeks post fertilization [10]. The adaptive immune system is
highly analogous to that of mammals, with T cells and B cells
that have Rag-dependent V(D)J recombination (reviewed
extensively in [9]). Finally, the zebrafish research community
benefits from an up-to-date database of techniques, genetic
strains, and other useful resources at http://zfin.org/.
In this paper, we focus our discussion on larval and adult
zebrafish models that recapitulate human diseases, focusing
on four separate branches of pathology: wound heal-
ing/restitution, gastrointestinal disease, microbe-host inter-
actions, and genetic diseases and drug screens.
2. Wound Healing/Restitution
Wound healing represents a critical biological response of
injured tissues and organs. Events causing epithelial injury
and barrier breakdown initiate a biological response known
as “restitution”, which is aimed at resealing the damaged
region and reestablishing host homeostasis. This “wound
healing” response involves migration of epithelial cells
toward the injured regions as well as epithelial cell prolifer-
ation to replenish the cell pool. Understanding the cellular
and molecular mechanisms regulating this response could
have profound translational impact for patients suffering
from chronic inflammation, ischemia/hypoxia, burn injury,
and cancer. The powerful imaging modalities available to
zebrafish researchers alongside their ease of genetic manip-
ulation make this vertebrate system an ideal model for
studying wound healing response to various injuries [11].
Additionally, the ability of zebrafish to regenerate both limbs
and cardiac tissue [12] makes them a powerful animal model
for understanding the molecular mechanisms involved in
regenerative signaling.
The most popular zebrafish injury model is the larval
tail wounding model, where a segment of the tail fin is
resected. Using this injury model with transgenic zebrafish
expressing EGFP under the transcriptional controlled of
the neutrophil-specific myeloperoxidase (MPO) promoter—
Tg(BACmpx:GFP)i114—investigators studied real-time neu-
trophil chemotaxis to the site of injury [13]. In this study,
they observed retrograde chemotaxis of neutrophils toward
the vasculature alongside where injury resolution was ob-
served, suggesting for the first time that retrograde chemo-
taxis may play an important role in the resolution phase of
the inflammatory response [13]. To determine the function
of the reactive oxygen species H2O2 in the wound healing
response, investigators injected mRNA encoding for the
hydrogen peroxide sensor HyPer to one-cell stage developing
zebrafish embryos [14]. Upon tail wounding of 3 dpf larvae,
the HyPer sensor demonstrated increased H2O2 production
along a gradient decreasing away from the wound site,
which signaled leukocyte chemotaxis to the injured location
[11]. Using pharmacological and morpholino blockade,
the authors showed that generation of the H2O2 gradient
is dependent on the activity of the dual oxidase (duox)
gene. This HyPer reporter system has also been utilized in
the study of neuronal regeneration, an important area of
study for the treatment of many human diseases. H2O2
produced by injured keratinocytes was shown to induce
somatosensory axonal regeneration in zebrafish. Similar to
the tail fin wounding model, neuronal regeneration required
activation of duox [15]. Moreover, H2O2 administration
promoted axonal regeneration following neuronal injury,
even without accompanying keratinocyte injury [15]. These
results expand the understanding of posttraumatic nerve
injury and subsequent loss of limb function in humans.
The healing-enhancing properties of H2O2 have since been
extended to studies in both rabbits [16] and horses [17] as
well as one reported case study in a human patient [18].
Beyond cutaneous wounds, zebrafish have been used for
the ability to regenerate cardiac tissue. Unlike mammals,
which form scars and do not regenerate cardiac tissue follow-
ing injury, zebrafish are able to fully regenerate their heart
within 2 months after 20% ventricular resection [19]. This
ability for zebrafish to overcome scar formation requires acti-
vation of Mps1, a mitotic checkpoint kinase [19]. Addition-
ally, cardiac regeneration involves upregulation of wound
healing genes and proliferative factors including apoeb, vegcf,
and granulina (all of which have human analogs) and likely
activation of platelet-derived growth factor B signaling [20].
Cardiac regeneration studies in zebrafish could produce
novel paradigms and identify unique pathways/targets with
profound translational impact for patients suffering from
ischemic heart disease.
3. Gastrointestinal Diseases
The zebrafish gastrointestinal system is highly homologous
to that of mammals, containing a liver, pancreas, gall bladder,
and a linearly segmented intestinal track with absorptive
and secretory functions [21, 22]. The intestinal epithe-
lium displays proximal-distal functional specification and
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Table 1: Zebrafish gastrointestinal models of pathology.
Model Mechanism of pathology Human relevancy/key features Key references
Pan-GI neoplasias Heterozygotic APC mutation
APC mutations drive spontaneous
and genetic intestinal
adenocarcinomas.




Human genetic overlap. Rising
prevalence of HCV-driven HCC in
humans.
Lam and Gong, 2006 [25]
Rekha et al., 2008 [26]
Pancreatic cancer Transgenic ptf1a-KRAS zebrafish
Recapitulates hedgehog signaling
aberrations found in humans.
Elucidates a potential cellular origin
for pancreatic cancers.
Park et al., 2008 [27]
Inflammatory bowel disease
TNBS in the media of zebrafish
larvae
Model inflammatory and goblet
cell hypertrophy. Responds to
bacterial status and IBD
medications.
Flemming et al., 2010 [28]
Oehlers et al., 2011 [29]
Inflammatory bowel disease
Oxazolone enema in adult
zebrafish
Goblet cell depletion and eosinophil
infiltration. Responds to antibiotic
therapy.
Brugman et al., 2009 [30]
NAFLD





Large lipid filled hepatocytes and
cellular apoptosis; pathology linked
to ER stress responses. Alternative
model generates a fatty liver and
hepatocyte apoptosis.
Cinaroglu et al., 2011 [31]
Amali et al., 2006 [32]
(alternative model)
Alcoholic liver disease
2% ethanol to the water of 4 dpf
zebrafish for 32 days
Hepatomegaly and steatosis, with
upregulation of genes involved in
toxic alcohol metabolism. Model is
sensitive to sterol regulatory
binding protein, important in
human disease.
Passeri et al., 2009 [33]
Abbreviations: GI: gastrointestinal; APC: adenomatous polyposis coli; HCV: hepatitis C virus; TNBS: 2,4,6-trinitrobenzene sulfonic acid; IBD: inflammatory
bowel diseases; NAFLD: nonalcoholic fatty liver disease; ER: endoplasmic reticulum.
contains many of same epithelial cell lineages found in
mammals including absorptive enterocytes, goblet cells, and
enteroendocrine cells [21, 22]. Enterocytes have a basolateral
nuclei and form tight junctions, apical microvilli, and an
intestinal brush border [23]. In the last decade, numer-
ous gastrointestinal pathologies have been modeled in the
zebrafish, as summarized in Table 1.
Interestingly, a forward genetic mutagenesis screen (N-
ethyl-N-nitrosourea (ENU), see section five) generated ze-
brafish mutants that develop spontaneous intestinal, pan-
creatic, and hepatic neoplasias [24]. These mutants were
later found to be heterozygotic for a truncated form of
APC, thereby leading to accumulation of nuclear β-cate-
nin and increased expression of downstream genes such
as cmyc and axin2 [24]. Adding the carcinogen 7, 12-
dimethylbenz[a]anthracene to these mutant zebrafish in-
creases the frequency of tumor development. Since germ-
line-truncated APC mutations in both humans [34, 35] and
mice [36] result in the spontaneous development of a large
numbers of intestinal polyps, the APC zebrafish model could
be useful in genetic, drug screening, and toxicology studies.
There are roughly 24,000 new cases of hepatocellular
carcinoma (HCC) annually in the United States, resulting
in over 18,000 deaths per year [37]. Worldwide, the disease
incidence can be as much as 30-fold higher due to the
increased prevalence of hepatitis infections [38]; globally
estimated 564,000 new cases occur per year, accounting for
5.6% of all human cancers [38], and resulting in similar rates
of mortality as seen in the USA [38]. Oncogenomic profiling
of liver tumors showed a significant overlap between human
and zebrafish in 132 genes [25]. These genes included those
involved in β-catenin and Ras-MAPK signaling pathways
as well as genes implicated in cellular adhesion, apoptosis,
and liver-specific metabolism found in both organisms [25].
HCC can be induced in zebrafish with the liver toxin
thioacetamide, resulting in HCC-related pathology within 12
weeks of exposure. The timeline of thioacetamide-induced
HCC could be significantly accelerated (6 versus 12 weeks) by
using transgenic fish expressing the hepatitis C virus (HCV)
core protein (HCP-transgenic fish) [26]. The increasing
prevalence of HCC in humans has been attributed to the rise
of HCV infection [39], in particular through the oncogenic
action of the HCV core protein [40], making this model
particularly relevant to human disease.
Pancreatic cancer represents the fourth most common
cause of cancer-related mortality in the western world, likely
due to limited diagnostic tools and inability to survey the
disease. Exocrine pancreatic cells are responsible for more
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than 95% of pancreatic cancer [37]. The cell population in
the pancreas that gives rise to human exocrine pancreatic
cancer remains unknown and investigators have turned to
zebrafish models to investigate this important question.
Transgenic zebrafish were generated using a bacterial arti-
ficial chromosome (BAC) approach that expressed EGFP-
KRAS fusion protein under the control of the zebrafish
pancreatic locus ptf1a (Tg(pft1a:EGFP-Hsa.KRASG12V )jh7
[27]. Using these fish, investigators found that while normal
pancreatic cell progenitors differentiated normally, KRAS-
transgenic fish had blocked cellular differentiation, produc-
ing a pool of undifferentiated progenitors that progressed to
invasive pancreatic cancer over a course of 3 to 9 months.
These cancer cells also had increased expression of multiple
hedgehog genes (shh, dhh, ihha, ihhb) as well as the down-
stream hedgehog targets Ptc2, ptc1, and gli1. This aberrant
signaling pattern seen in these pancreatic tumor cells was
also typical of human pancreatic cancer [27]. This zebrafish
model established for the first time that oncogenic exocrine
pancreatic progenitor cells could be the cellular origin for
pancreatic cancer.
Outside of cancer models, one area of gastrointestinal
disease that has received significant attention in recent years
is the development of zebrafish models of Inflammatory
Bowel Disease (IBD). In humans, IBD is the result of dysreg-
ulated interactions between a genetically susceptible host and
their commensal gut microbiota [41–43]. IBD is primarily a
disease of the Western world; it affects 1.4 million Americans
and there is no cure for the disease [44]. Outside of North
America, similar disease burdens are seen in Europe but are
∼3-fold lower in Asia and the Middle East, with the exception
of Japan [45]. Pharmacological treatment centers around the
use of anti-inflammatories and immunosuppressants, and
surgical management of the disease is also possible though
not always curative [46]. Numerous chemicals and genetic
approaches are currently used by the IBD research commu-
nity to study this pathology. These models mimic various
aspects of the disease, such as disrupted barrier function
and impaired innate and adaptive immune responses [47,
48]. Among the chemical models, the hapten oxazolone has
been used for studies of acute intestinal inflammation. This
murine model consists of rectal administration of a single
dose of oxazolone dissolved in ethanol, resulting in an acute
colitis lasting up to 10 days, with peak inflammation at 2 days
post administration in mice [49]. The model is characterized
by a strong Th2-dependent immune response that can be
abrogated by IL-4 neutralizing antibodies and has similar
characteristics to human ulcerative colitis [48].
Investigators have tried to adapt the hapten oxazolone
model of colitis to adult zebrafish. Brugman et al. showed
intestinal epithelial damage and goblet cell depletion in
oxazolone-treated fish within 5 hours of treatment, which
lasts for up to 7 days [30]. This was accompanied by eos-
inophil infiltration into the intestine with increased il1b, tnf,
and il10 gene production compared to untreated zebrafish.
The inflammatory phenotype was reduced by the adminis-
tration of the gram-positive-specific antibiotic vancomycin,
suggesting a role for commensal bacteria in the inflammatory
process of this model. The main constraint of this model
is the need to use adult, nontransparent zebrafish which
severely limits imaging capability. In addition, the need to
rectally administer each individual zebrafish with oxazolone
represents a technical challenge.
The hapten 2,4,6-trinitrobenzene sulfonic acid (TNBS) is
another popular mammalian model of colitis characterized
by a Th1-driven immune response [48] that is used for the
study of both acute and chronic intestinal inflammation. In
the acute model, TNBS is dissolved in ethanol and rectally
administered in a single dose, while the chronic model can
have multiple administrations weekly over a period of
months [50]. The ethanol is responsible for disrupting the
intestinal barrier while the TNBS serves to activate the
immune system [48]. Two research groups have developed
a larval model of colitis by exposing 3 dpf zebrafish for 3–
5 days to TNBS in the fish media [28, 29]. Using the MPO
reporter strain (Tg(BACmpx:GFP)i114) these investigators
noticed neutrophil infiltration throughout the zebrafish [13],
gut-specific increases in il1b expression, altered intestinal
lipid metabolism, goblet cell hypertrophy, and intestinal
shortening. This larval TNBS model presents several advan-
tages, including a dose-dependent phenotype, a sensitivity to
antibiotics treatment, and a response to anti-inflammatory
agents (5-ASA and prednisolone) widely used to treat human
IBD [29]. However, the intestinal histopathologies are poorly
characterized in this model. In addition, the inflammatory
component appears mostly to be nonintestine specific. Fur-
thermore, no intestinal epithelial cell damage is observed
histologically [29], suggesting a lack of significant intestinal
injury. Finally, it is unclear how a hapten could cause an
inflammatory reaction in larvae missing a functional adapt-
ive immune system.
We have recently established a model of epithelial injury
in zebrafish using the NSAID glafenine [51]. Administration
of glafenine to 5 dpf zebrafish for 12 hours results in a
dramatic increase in intestinal epithelial cell apoptosis. This
intestinal-specific apoptotic response is mediated by induc-
tion of endoplasmic reticulum (ER) stress and is accompa-
nied by attenuation of the unfolded protein response (UPR)
coupled to an improper activation of downstream UPR
mediators such atf6 and s-xbp1. Interestingly, loss of XBP1 in
IECs results in the development of spontaneous enterocolitis
in mice [52] and polymorphisms of this gene are associated
with human IBD [53].
Chronic liver disease is responsible for over 25,000 deaths
annually in the United States and represents the tenth
leading cause of death, with a prevalence of over 5.5 million
patients in 1998 [54] and that has since been estimated to
affect up to 30% of the US population [55]. In the UK,
the picture is grimmer, as it is the fifth leading cause of
death [56]. Nonalcoholic fatty liver disease (NAFLD) is a
highly prevalent form of severe chronic liver disease, affecting
3% of all adults in America [57]. It also has significant
associated mortality, with a 5-year survival of 67% and 10-
year survival of 59% [57]. Additionally, up to one-third
of all Americans have some level of NAFLD [56]. Outside
of the USA, where obesity is less prevalent, rates are also
increasing. In Italy, which is traditionally considered low
risk, an incidence of NAFLD of 20–25% of the population
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has been recently been reported [56]. In China and Japan,
the disease incidence has been reported at 15% and 14%
of the population, respectively [56]. There is no identifiable
cause of NAFLD, but the pathology is linked to obesity,
diabetes, and hyperlipidemia. Treatment involves managing
these complex etiologies, and pharmacological therapies spe-
cific for NAFLD are not available for these patients [57].
Consequently, significant work has been invested to develop
reliable zebrafish larvae models of liver pathology that could
be easily utilized for drug targeting and screening.
The most characterized zebrafish model of NAFLD
involved a forward genetic screen using viral insertion and
screening for hepatomegaly. In the case of the NAFLD model,
a 172 bp gene trap cassette was found to be inserted in the
intron between exons 11 and 12 of the recently discovered
zebrafish gene foie gras (foigr) [58], which results in a
frame shift mutation, and generation of a stop codon. This
mutation (foigrhi1532b) results in the development of steatosis
(fatty liver disease) resembling human NAFLD, characterized
by large lipid filled hepatocytes and cellular apoptosis in
larvae as young as 5 dpf [58]. However, the exact function of
this gene, which is highly conserved across species including
humans, is not yet determined. Further studies with the foigr
mutant have shown that the apoptosis observed involves
increased ER stress and is regulated in part through the
UPR gene atf6. Morpholino blockade of atf6 ameliorates liver
injury during chronic ER stress in the foigr mutants [31].
However, atf6 blockade potentiates steatosis during acute
ER stress induced by the toxin tunicamycin [31], suggesting
that atf6 may have variable effects in different phases
(acute/chronic) of liver injury. Hepatic steatosis has also
been induced in zebrafish larvae using thioacetamide [32].
Investigators have showed that administration of 0.025%
thioacetamide into the fish media at 3 dpf resulted in liver
damage by 5 dpf, characterized by increased accumulation
of fatty droplets, hepatocyte apoptosis, and upregulation
of apoptotic genes such as bad, bax, p-38a, caspase-3 and
8, and jnk-1. Overall, the availability of NAFLD zebrafish
models is burgeoning, and they are poised to be screened
for pharmacological compounds that could for the first time
effectively treat this disease.
Alcoholic fatty liver disease (ALD) is estimated to be
involved in over 50% of all deaths due to liver failure second-
ary to liver cirrhosis, but accurate estimates for prevalence
are unavailable [54]. Binge drinking leads to transient fatty
liver disease, but chronic alcohol consumption can lead to
fibrosis, cirrhosis, and steatohepatitis [59]. An ALD model
has also been developed in zebrafish with administration
of 2% ethanol to the water of 4 dpf zebrafish for 32
days. This regimen results in hepatomegaly and steatosis,
alongside upregulation of hepatic cyp2e1, sod, and bip
gene expression—indicating hepatotoxic metabolism of the
ethanol [33]. Importantly, ethanol-induced steatosis was
prevented by morpholino blockade of the sterol regula-
tory binding protein (Srebps). Because Srebps activation is
important in chronic alcoholic liver disease [33] in humans,
the zebrafish ALD model could be utilized to identify
new therapeutic mechanisms and to screen for therapeutic
agents.
4. Microbe-Host Interactions
The ability to generate germ-free and gnotobiotic zebrafish
[60] has led to an increasing interest in understanding cellu-
lar and molecular mechanisms of microbial-host interactions
using zebrafish. Microbial-host interactions have received
significant interested in recent years and have been impli-
cated in a wide variety of human diseases, including CRC
[61], IBD [42, 43], obesity and diabetes [62], intestinal heal-
ing [63], irritable bowel syndrome [64], and inflammatory
nociception [65]. Zebrafish are host to gram-positive and
gram-negative bacteria, mycobacteria, protozoa, and viruses
[66], also allowing for their use as a model for infectious
diseases. In most cases, microorganisms associated with these
pathologies are not intrinsically pathogenic but are rather
part of the normal, commensal biota. The organ exposed to
the highest amount of microorganisms in the human body is
the gastrointestinal (GI) tract, especially the distal ileum and
colon. Because of the high prevalence of bacteria and bacte-
rial products in the GI tract, investigators have studied mech-
anisms controlling homeostasis in the face of such highly
antigenic materials. The zebrafish GI tract also harbors the
highest concentration of bacteria and as such represents an
interesting model to study bacterial/host interactions.
Bacteria and their associated products such as DNA,
RNA, and membrane structures (peptidoglycans, LPS—
lipopolysaccharide) are typically detected by a series of innate
sensors that are evolutionary conserved. A survey of the
zebrafish genome has identified numerous innate sensors
from the TLR and the Nod-like receptor family as well as
their associated signaling pathways [67]. An almost complete
set of TLRs (TLR1-5, 7-9, 21 [68]) exist in zebrafish, as do the
intracellular sensors Nod1 and Nod2 [69]. Associated innate
signaling proteins have also been identified in zebrafish such
as myeloid differentiation primary response gene (MyD88)
[68, 70], TIR domain-containing adaptor inducing IFN-β
(TRIF) [71], and NF-κB [72, 73].
The most studied bacterial product is arguably the gram-
negative-derived LPS. In mammals, LPS is detected by TLR4,
in association with the coreceptors MD2 and CD-14 [74].
Once engaged, TLR4 recruits the adapter protein Myd88
or TRIF to propagate the signal to NF-κB [75] and the
interferon responsive factor (IRF) 3, respectively [76]. This
signaling cascade plays a critical role in host response to
microbes and microbial products. As in humans, high doses
of LPS are toxic to zebrafish [77]. Studies using commensal
and germ-free zebrafish established that intestinal alkaline
phosphatase (iap), known to detoxify the endotoxic lipid
moiety A of LPS in mammals, is induced following micro-
bial colonization [77]. Knockout of iap resulted in exces-
sive intestinal neutrophil infiltration, a process involving
functional myd88 and tnfr as determined by morpholino
blockade [77].
Another important TLR system is TLR5, which detects
flagellin and activates various signaling pathways including
NF-κB [74]. Similarly to mammals, zebrafish detect flagellin
(Salmonella derived in these experiments) to induce multiple
matrix metalloproteinase genes as well as the inflammatory
markers il1b, il8, ifn, and cxcl-C1c [78]. Morpholino blockade
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showed that flagellin-induced Il1b and metalloproteinase 9
(mmp9) were myd88 dependent whereas ifn and il8 were
activated through another signaling system [78].
The functions of some of these TLR downstream
signaling adaptors have also been studied in zebrafish. Both
red and green transgenic Myd88 reporter strains such as
Tg(myd88:EGFP)z163 and Tg(myd88-DsRED2)z164 have
been developed [70]. These strains have been crossed to both
macrophage (Tg(lyz:DsRED2)nz50 [79]) and neutrophil
(Tg(BACmpx:GFP)i114 [13]) reporter strains to monitor
myd88 signaling. Studies with these dual-reporter fish
demonstrated that MyD88 colocalized with both macro-
phages and neutrophils and that these myd88-expressing
leukocytes migrated to wound sites and were involved in
bacterial phagocytosis [70].
Another downstream mediator of LPS signaling, acting
independently of MyD88, is TRIF. While zebrafish TRIF
shares only 32% homology with the human protein, like in
mammalian systems it can induce IFN and NF-κB luciferase-
reporter responses as seen using an overexpression system in
human HEK293T cells [71]. Interestingly TRIF-dependent
gene induction through the TLR4 pathway was found
to be nonfunctional in experiments with adult zebrafish
stimulated with LPS [71]; however, this is to be expected
given that zebrafish TLR4 paralogues (tlr4a and tlr4b) do not
recognize LPS [80, 81].
Outside of the TLRs, the intracellular sensors Nod1
and Nod2 are critical innate signaling systems in mammals.
Importantly, Nod2 was the first innate signaling molecule to
be genetically linked to Crohn’s disease susceptibility [82].
The exact protective role of Nod proteins in mammals is not
fully understood but defective bacterial killing appears to be
an important factor [82–84]. Both nod1 and nod2 genes are
expressed in IECs and neutrophils of zebrafish. Functional
studies using morpholino blockade showed that Nod2 plays
an important role in setting host antimicrobial properties
[69]. Interestingly, Nod1 or Nod2 depletion resulted in
increased susceptibility to Salmonella infection in a zebrafish
embryonic infection model [69]. This study suggests that the
antimicrobial properties of Nod2 are conserved in zebrafish.
As mentioned previously, NF-κB signaling is an impor-
tant effector pathway downstream of numerous innate
sensor systems [85]. Colonization of germ-free NF-κB; EGFP
reporter zebrafish Tg(NFkB:EGFP)nc1 with a commensal
microbiota induced NF-κB activation and expression of NF-
κB target genes including complement factor b (cfb) and serum
amyloid a (saa) in intestinal as well as in extraintestinal
tissues of the GI tract [86]. Activation of NF-κB signaling
in zebrafish indicates an important role of this transcription
factor in maintaining host homeostasis that is conserved
across species. The ability to longitudinally study NF-κB
activation in a cell-type specific fashion in response to
various microbial stimuli makes the zebrafish a powerful sys-
tem to decipher complex host-microbe interaction. Overall,
the recent development of the aforementioned technologies
makes the study of microbial-host interactions in zebrafish a
burgeoning area of research.
Response to infection is another area of microbial-
host interaction that has received significant attention in
zebrafish. The most studied and prominent zebrafish infec-
tious model is the M. marinum model, which is highly
analogous to the human infectious agent M. tuberculosis,
the etiologic agent for Tuberculosis (TB). TB is a growing
epidemic worldwide, with over 83 million cases reported
between 1990 and 1999, resulting in over 3 million deaths
annually [87]. Many strains of the infectious bacteria are
becoming drug resistant, resulting in an increase in global
disease burden, including in the Unites States [88]. Finding
new drugs to combat the ongoing threat of TB is conse-
quently essential, as the disease can no longer be contained
with current medications [89]. Coincubation of M. marinum
with 5 hpf embryos results in the formation of macrophage-
driven granulomas within 5 dpf [90], a hallmark of TB
pathology. In vivo imaging and macrophage depletion
showed that granulomas, traditionally thought to be a host-
protective mechanism, may in fact be a source of early TB
tissue dissemination by passing M. marinum into uninfected
macrophages during phagocytosis [91, 92]. Consequently,
this system has provided novel insights into the pathological
mechanisms of TB infection and its interactions with the host
immune system and is poised to be used as a drug screen to
identify novel anti-TB compounds.
Other pathogens have also been studied in zebrafish.
These include S. aureus, S. pyogenes, and S. typhimurium.
These and other infectious models in zebrafish have recently
been reviewed in detail by Meeker and Trede [9]. Although
very informative, these studies were not performed using a
natural route of infection but rather by using direct delivery
(injection) into embryos at various developmental stages.
However, oral gavage technology in larvae would likely
improve the physiological relevance of infectious models per-
form in zebrafish. Another limitation of zebrafish infection
models is the difference in host temperature; zebrafish and
their natural pathogens exist at a temperature of 28◦C, while
many human-relevant pathogens are only infectious at 37◦C
[9]. Finally, there is some evolutionary divergence in TLR
signaling that must be taken into account when working
with this organism. Specifically, in contrast to mammals, LPS
is not sensed by zebrafish TLR4 and the sensor negatively
regulates MyD88 signaling [80]. Despite these limitations,
zebrafish remain a powerful tool for studying microbe-host
interactions [67].
5. Genetic Diseases and Drug Screens
Because of their high fecundity, transparency, and ease
of imaging, zebrafish are particularly well suited for
genetic screening approaches. Forward and reverse genetic
approaches can be undertaken to generate new zebrafish
phenotypes and identify new genes of interest with potential
relevance to human disease phenotypes. Zebrafish disease
models can also be screened in a cost- and time-effective
manner to discover disease-suppressing compounds. Using
a whole organism is a particularly appealing aspect of
zebrafish-based screens, since complex cell-cell and organ-
organ interactions are kept intact.
There are two main approaches to forward-genetic
screens in zebrafish that have been undertaken thus far. The
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first involves exposing males to the mutagen ethylnitrosourea
(ENU) and then screening for a phenotype [93, 94] shared
by all mutants, such as renal cysts or heart failure. ENU
is an alkylating agent that typically induces A→T base
transversions. Zebrafish are relatively resistant to the ENU
toxic side effects, allowing for higher dosages and thus
increased rates of mutation [95]. An alternative mutagenesis
approach employs random retroviral insertion [96, 97].
While this retroviral method is only one-ninth as efficient at
generating a mutation as the ENU approach, it circumvents
the need for positional cloning by tagging each insertion
event, saving significant screening effort once a phenotype
is found.
Duchenne muscular dystrophy (DMD) affects 1 in 3500
males and causes progressive muscle degeneration that can
lead to death. DMD is the result of mutations in the sarcolem-
mal protein dystrophin located on the X-chromosome [98].
During an ENU screen of zebrafish [94], a mutation referred
to as sapje [99] was discovered. This mutation was later found
to be located in the zebrafish Duchenne muscular dystrophy
(dmd) gene and causes progressive muscular degeneration
in zebrafish larvae [100]. Electron microscopy showed that
muscular degeneration was the result of failure to form
proper muscle attachments at the myotendinous junction.
This pathological mechanism was hypothesized to occur in
mammals but was lacking concrete evidence, making the
zebrafish a novel system for studying the pathophysiology of
this devastating disease.
The most common form of heritable polycystic kidney
disease (PKD) is autosomal dominant PKD. This disease
affects more than 1 in 1000 live births and approximately
10% of patients with PKD will require kidney transplant
due to renal failure [101]. PKD has been linked to defects
in primary cilia formation and function in humans [101].
This disease has also been successfully modeled in zebrafish
by using retroviral insertion mutagenesis and screening for
cystic kidneys in 5 dpf larvae [102]. The screen discovered
12 genes whose loss formed cysts in the glomerular-tubular
region, including two already associated with human disease
(vhnf1 and pkd2), demonstrating genetic and phenotypic
homology between humans and zebrafish. Three of the
10 remaining genes are homologues of Chlamydomonas (a
genus of green algae) genes, which encode components of
intraflagellar transport particles involved in cilia formation
[102], but have yet to be analyzed in human PKD patients.
The other 7 genes discovered provide completely novel
targets for studying the underlying genetics and mechanisms
of PKD, as many of the genes that can result in PKD remain
unidentified in humans [101].
Dilated cardiomyopathy (DCM) is the cause of at least
half of the 5.8 million heart failure cases in the USA, typically
resulting from prior heart damage due to a myocardial
infarction or an infection [103]. Worldwide, DCM is the
leading indicator for heart transplant [104], with incidences
to be as high as 9.6 per 100,000 person-years in Europe
[104] and China [105]. DCM results in poor heart function
that eventually leads to death [103]. ENU zebrafish screens
discovered numerous fish with cardiac abnormalities [93,
106, 107]. Two of these mutants, sih and pickwickm171, were
found to have dilated hearts with thin walls and defective
contractility [108, 109]. Further analysis showed that the sih
(silent heart) mutants had a mutation in cardiac troponin T
gene [108], while the pickwickm171 mutants had a mutation
in the titin gene [109]. Since both of these genes are known
to be important in human DCM, these mutants zebrafish
represent interesting and complementary models to study
this pathology.
All of the aforementioned models demonstrate that
forward genetic screens in zebrafish can generate specific
phenotypes that are highly homologous to human diseases.
Further analysis of these mutants almost invariability leads
to the identification of a gene with high homology and
relevance to corresponding human disease.
Targeted, reverse genetic approaches are also quite suc-
cessful in generating models of disease, especially if a homo-
log exists between the human gene(s) driving the disease and
the zebrafish. One disease that has recently been modeled
in zebrafish using a reverse-genetic approach is Hutchinson-
Gilford progeria syndrome (HGPS), a rare (1 : 4,000,000 peo-
ple) premature senescence syndrome that generally results
from sporadic mutations that disrupts conversion of prel-
amin A to mature lamin A [110]. HGPS patients have
markedly aberrant development characterized by lipodys-
trophy, osteolysis that is most pronounced in the cranium,
and coronary dysfunction [110]. The mean life expectancy
for patients with HGPS is less than 13 years. In zebrafish,
investigators were able to use a combination of directed
loss of function mutations and morpholino knockdowns
of prelamin and progerin to generate zebrafish that were
able to live to adulthood (though with shortened lifespans).
These fish had both phenotypic and molecular signs of
early senescence, including lipodystrophy, aberrant muscu-
lature and craniofacial skeletal structure, increased cellular
apoptosis, and cell-cycle arrest [111]. These phenotypic
manifestations align remarkably well with those seen in
human HGPS, demonstrating a proof of concept for reverse
genetic approaches to developing zebrafish models of human
diseases.
Some of the mutants generated during forward-genetic
screens have been subsequently subjected to drug screening
methodologies. The ability to rapidly and easily image
large numbers of developing zebrafish makes them highly
tractable as a preclinical system for drug screens [112]. A pro-
totypical example of drug screening in mutant zebrafish dis-
covered with the ENU forward-genetic approaches involves
the gridlock (grl) mutant. The grl mutant lacks blood flow
to the posterior trunk and tail due to a localized block in
caudal blood flow at the base of the dorsal aorta [113].
This model has many characteristics similar to the human
congenital disease coarctation of the aorta, making it of
significant clinical interest. Coarctation of the aorta involves
narrowing of the aorta that affects 1 in 2,500 live births [114].
It is the fifth most common form of congenital heart defect,
and without surgical treatment the mean age of survival is
only 31 years of age [114]. Surgical intervention can prevent
early death, but significant morbidity, usually in the form
of hypertension, can persist and results in decreased life
expectancy [114]. Unfortunately, no clear etiology of the
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disease exists, and the grl model in zebrafish is the best
animal model currently in existence for the study of this
disease [114].
The grl zebrafish has a hypomorphic mutation in the
hey2 gene, a basic helix-loop-helix protein involved in aortic
development [115]. Gene titration studies using morpholino
technology demonstrated that dose-dependent loss of this
gene results in ablation of progressively larger sections of the
aorta and expansion of the contiguous region of vein [116].
A pharmacological screen, assessing restoration of blood
flood and survival of larvae using bright-field microscopy,
found that two structurally related compounds (GS3999
and GS4012, unknown targets) promoted activation of the
vascular endothelial growth factor (VEGF) pathway and
were able to rescue the phenotype [117]. Another unre-
lated screen found that phosphoinositide-3-kinase (PI3K)
inhibitors were also able to rescue the phenotype by driving
VEGF activation [118]. This included the uncharacterized
flavone GS4898, a structurally similar compound to the PI3K
inhibitor LY294002, and the PI3K inhibitor wortmannin.
This work also demonstrated for the first time that ERK sig-
naling in embryos drives aortic differentiation, while activa-
tion of PI3K signaling produces a venous fate. These findings
have since been recapitulated in a murine system and have
provided new insights into arterial morphogenesis [119] as
well as generated some of the first insights into the underly-
ing mechanisms behind coarctation of the aorta in humans.
A pair of robust screens has also been performed to eval-
uate compounds known to induce prolonged QT intervals in
humans in the hopes of developing a preclinical cardiac toxi-
city screen. Cardiac QT elongation, which can cause the fatal
heart arrhythmia known as Torsade de Pointes, is required
to be evaluated in clinical drug trials [120] and thus these
screens are of great clinical importance. Two such screens to
evaluate bradycardia, atrioventricular blockade and arrhyth-
mias in zebrafish have been performed thus far [121, 122].
In the first study 100 biologically active compounds were
screened and 18 of the 23 that caused arrhythmias in humans
were also positive in the zebrafish, while postscreen analysis
showed that poor absorption explained 4 out of 5 of the
false-negatives [122]. Additionally, the combination of ery-
thromycin and cisapride was also positive during screening
while each drug alone was not, recapitulating a known
drug-drug interaction that causes arrhythmias in humans.
Consequently, the zebrafish hold significant promise to be
used as a screen to evaluate new drugs for their potential to
generate this serious and often fatal side effect.
6. Overall Limitations
The use of zebrafish as a model organism for studying human
disease is a relatively new and emerging field of research.
Consequently, the number of available zebrafish strains
and facilities that house zebrafish is much smaller than
for well-developed model higher vertebrate organisms such
as the mouse. Additionally, very few validated zebrafish
reagents such as antibodies and cell lines are available to the
research community. This significantly curtails the in-depth
investigation of molecular and cellular details implicated in a
given phenotypes.
Zebrafish also have numerous duplicate genes [123],
which significantly complicate generation of knockout
strains using either forward or reverse-genetic approaches.
Forward-genetic approaches that disrupt one gene copy
likely will not disrupt the second copy, and duplicate genes
also make targeted knockout strategies more difficult as both
copies must be deleted. Additionally, while the zebrafish
genome has been fully sequenced, the annotation is still
limited and more of a work in progress. Furthermore com-
parative genomic analyses between zebrafish and the human
or murine genome counterparts have yet to be performed.
Zebrafish also have environmental conditions that differ
substantially from humans. They must be raised in water
with specific ionic concentrations and temperature (28◦C).
Consequently, some water-insoluble small molecules cannot
be administered to zebrafish because carrier solvents (such as
EtOH or DMSO) would reach toxic levels before solubility is
achieved. Additionally, since drugs are administered directly
to the fish media, bathing the entire fish in the test compound
can result in nondesired toxic side effects. An example in our
hands was the attempt to use dextran sodium sulfate (DSS)
to induce colitis in larval zebrafish. At concentrations as low
as 0.01% (v/v) the surfactant properties of the DSS choked
the gills of the zebrafish, resulting in their death before an
intestine-specific effect could be observed (Goldsmith and
Jobin, unpublished observation). As discussed in a previous
section, the development of an oral gavage approach could
circumvent this important limitation.
7. Perspectives
Animal models have been used since the inception of medical
research. For most models of human disease, the preferred
and most utilized animal system of human disease is
overwhelmingly the murine system. Despite the tremendous
gain of knowledge provided by using murine experimental
systems, the long gestation time (18–20 days) and sexual
maturation rate (6–8 weeks) combined with high cost
of housing and breeding represent significant limitations.
Furthermore, experiments with mice are labor intensive and
not particularly well suited for high-throughput screening.
These limitations have spurred the need to develop other
model organisms that could be used to provide initial gene
or drug targets information before beginning investigations
in more expensive systems.
Transparent, larval zebrafish models have the potential
to fill this important niche in the study of human disease,
enabling rapid, physiologically relevant in vivo screening.
The transparent nature of zebrafish also allows for real-
time imaging of pathogenesis, which has already provided
key insights into the molecular mechanisms of metastasis
[124–127] and tuberculosis dissemination [90–92]. The
recent advent of the Casper fish promises to extend the
imaging capacity beyond larvae to adult fish, permitting
studies in fish with a functional adaptive immune system.
The zebrafish has already demonstrated profound bench-to-
bedside power, as evidenced by the rapid translation time
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(∼2-years) from the initial reports of the role of H2O2 in
neutrophil chemotaxis during wound healing in zebrafish
[11] to the first utilizations of such knowledge in human
patients [18].
The zebrafish remains a relatively underdeveloped model
organism with large amounts of untapped potential. As more
is understood about the comparative genome, anatomy, and
physiology of zebrafish to that of humans, the relevance and
utility of this vertebrate model will only grow and provide
a powerful complement to the murine system. Two decades
of research has demonstrated the power and relevancy of the
zebrafish in modeling human disease. Its unique properties
make it an ideal in vivo system for initial use in the
interrogation of a given pathology before translating the
observations made in the model organism to more expensive
murine systems.
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